Price$0.33+0.00 (+0.03%)
01:45 PM07:45 PM
News · 26 weeks96+17%
2026-04-192026-10-11
Mix2390d
- Market10(43%)
- Other6(26%)
- Insider3(13%)
- SEC Filings3(13%)
- M&A1(4%)
Latest news
25 items- NEWSCosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform● 60.5% of U.S. online checkout orders included a subscription, rising to more than 75% in recent days as adoption accelerates● $919,945 monthly subscription value at standard renewal pricing as of October 14, 2026● 2.4 product units per subscription on average, with 14,793 units across 12,408 active subscription lines● 10,881 U.S. online checkout orders tracked by the Company's subscription management platform CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM),
- NEWSCosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 DaysRecord day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date$902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day periodAccelerating: average daily sales of more than $60,000 over the past 10 days, double the 30-day averageApproaching U.S. target: the 10-day pace, if sustained, corresponds to approximately $21.9 million annualized, nearing the over $23 million in annual U.S. revenue the Company previously projected within 12 to 18 monthsPlatform to scale: the Company is evaluating extending the model to additional brands and markets CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc
- SECSEC Form 8-K filed by Cosmos Health Inc.8-K - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 MillionRecord nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025Nine-month 2026 revenue nearly matches the whole of 2024 - when full-year revenue was $54.4 million - and represents 83% of record full-year 2025 revenue of $65.3 millionRecord third-quarter revenue of approximately $17.4 million - exceeding the previous Q3 record of $17.1 million set in 2025, and up 40% on Q3 2024Every quarter of 2026 has set a record for its period - Q1, Q2 and Q3 each exceeded the highest revenue previously reported for that quarterGrowth across all core segments - contract manufacturing, pharmaceutical distribution and proprietary brands, with
- NEWSCosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 BillionMore than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded genericsProprietary brands sold in more than 40 countries - across Europe, the Middle East, North America and Asia, through pharmacies, hospitals, retail chains and e-commerceAddressable markets of approximately $946 billion - the six product categories and two service markets in which the Company competes are estimated by third-party research at approximately $946 billion in 2025, projected to reach approximately $1.76 trillion by 2033Infection control gaining hospital and retail traction - C-Scrub listed at T
- NEWSCosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized RevenueRecord Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarmRevenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18%Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to datePharmacies served daily up 3.6x, from ~100 in 2017 to ~360 today, within a total network of more than 1,500 pharmaciesOperating leverage from enhanced route density and optimized order execution - during 2025, reve
- NEWSCosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production PipelineContract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreementsGross margins of over 90% - among the highest-margin revenue streams in the Company, with raw materials largely supplied by clientsRecord production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with 7.7 million units added in September aloneDiversified across 11 therapeutic categories, reducing dependence on any single product or partner, under multi-year agreements averaging approximately four years, wit
- NEWSCosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million todaySecured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target PharmaCoverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flowsDivision targeted to generate over $10 million in recurring annual profit at full capacity 7.7 million contracted units added in under two weeks - Cana Laboratories
- NEWSCosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management MarketPrime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stockPositions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets.CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorptionIntellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and CanadaAddresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized
- NEWSCosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana LaboratoriesExpands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolioCumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026Further strengthens recurring cash flow visibility and expands Cana's long-term manufacturing relationships with established pharmaceutical companies 500,000 contracted units of ROSARTIA annually / 2.5 million o
- NEWSCosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health MarketFirst orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVetFormulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottleSales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinicsCertified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary useManufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integr
- PRCosmos Health: A Company Transformed — 2026 Year-to-DateA Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M. Full-year 2026 guidance: $90M+.ATW $8M convertible note retired 12 months early: No further conversions, no dilution.Strengthened balance sheet: H1 2026 total liabilities reduced 13.3% and stockholders’ equity increased 12.2%Simplified capital structure: No shelf registration, no ATM, no floorless warrants.5.1M+ shares repurchased for ~$1.11M under the $5M buyback.Management increasing ownership: CEO Greg Siokas personally incre
- PRCosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilutionSimplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floorOperating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost controlStrong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength$5.0 million share repur
- SECCosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program UnderwayHighest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 millionContinued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8%Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growthStrengthened balance sheet, with total liabilities decreasing 13.3% by $6.
- SECSEC Form 10-Q filed by Cosmos Health Inc.10-Q - Cosmos Health Inc. (0001474167) (Filer)
- SECSEC Form NT 10-Q filed by Cosmos Health Inc.NT 10-Q - Cosmos Health Inc. (0001474167) (Filer)
- INSIDERChief Executive Officer Siokas Grigorios bought $70,000 worth of shares (349,825 units at $0.20), increasing direct ownership by 2% to 14,597,917 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERChief Financial Officer Terzis Georgios was granted 328,407 shares, increasing direct ownership by 15% to 2,563,805 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERChief Executive Officer Siokas Grigorios bought $140,000 worth of shares (766,284 units at $0.18), increasing direct ownership by 6% to 14,248,092 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- PRCosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B ChannelsDigital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own packageCorporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account managementFuture platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kitsPlatform builds on the U.S. subscription launch of NOOR Collagen, which has deliv
- SECSEC Form RW filed by Cosmos Health Inc.RW - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 UnitsCosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer accessExpansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with Pharma Cell for the distribution of its Sky
- SECSEC Form S-8 filed by Cosmos Health Inc.S-8 - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market RepurchasesCHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million. Under the program, Cosmos Health may repurchase shares from time to time in the open market, through privately negotiated transactions, or through other permitted means, in accordance with S
COSM FAQ
5 questionsWhat does Cosmos Health Inc. do?
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and...Where does COSM stock trade?
Cosmos Health Inc. (COSM) is listed on NASDAQ.What sector and industry is COSM in?
Cosmos Health Inc. operates in the Health Care sector, Other Pharmaceuticals industry.What companies are similar to COSM?
Notable peers in the same industry include MCK (McKesson Corporation), COR (Cencora Inc.), CAH (Cardinal Health Inc.), ABC (AmerisourceBergen Corporation), CVET (Covetrus Inc.). Compare COSM side-by-side with any of them on Quantisnow.How can I track COSM on Quantisnow?
Quantisnow aggregates Cosmos Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COSM to receive live email and push alerts on every new disclosure.